Filing Flows › Viatris (VTRS) › Q2 2026 › vs Q2 2025
Viatris (VTRS) Q2 2026 vs Q2 2025 (year over year)
Viatris's revenue rose $175M (+5%) from $3.6B in Q2 2025 to $3.8B in Q2 2026. The biggest changes: Brands +$134M (+6%); Lipitor +$64.3M (+17%); Norvasc +$17.5M (+10%).
Viatris, Q2 2026: revenue $3.8B (+5% year over year), operating margin 0.2%, net loss $119M, operating cash flow $382M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 8.8% | 4.7% | +4.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Brands | $2.4B | $2.3B | $134M | +6% |
| Lipitor | $452M | $388M | $64.3M | +17% |
| Norvasc | $200M | $183M | $17.5M | +10% |
| Lyrica ® | $121M | $128M | −$7.5M | -6% |
| Viagra ® | $113M | $100M | $12.6M | +13% |
| Creon ® | $97.4M | $91.4M | $6.0M | +7% |
| Celebrex ® | $76.4M | $70.0M | $6.4M | +9% |
| Zoloft ® | $71.4M | $61.1M | $10.3M | +17% |
| Yupelri ® | $70.7M | $66.6M | $4.1M | +6% |
| Effexor ® | $66.7M | $63.1M | $3.6M | +6% |
| Dymista ® | $39.8M | $48.4M | −$8.6M | -18% |
| Amitiza ® | $39.4M | $41.6M | −$2.2M | -5% |
| Revenue | $3.8B | $3.6B | $175M | +5% |
| Net loss | $119M | $4.6M | $114M | 26× |
| Costs & expenses | $3.9B | $3.8B | $76.4M | +2% |
| Operating costs | $3.8B | $3.3B | $401M | +12% |
| Interest & other, net | $70.3M | $450M | −$380M | -84% |
| Income tax | $54.8M | −$212M | $267M | — |
| Cost of revenue | $2.3B | $2.2B | $51.1M | +2% |
| Operating cash sources | $711M | $715M | −$4.4M | -0.6% |
| Depreciation & amortization | $672M | $678M | −$6.0M | -0.9% |
| Share-based compensation | $38.7M | $37.1M | $1.6M | +4% |
| Net loss absorbed | $119M | $4.6M | $114M | 26× |
| Working capital & other | $210M | $491M | −$281M | -57% |
| Operating cash flow | $382M | $220M | $162M | +74% |
| Free cash flow (OCF − capex) | $329M | $167M | $162M | +97% |
| Capital expenditures | $52.8M | $52.9M | −$100K | -0.2% |
Questions
How much did Viatris's revenue grow year over year in Q2 2026?
Viatris's revenue rose $175M (+5%) from $3.6B in Q2 2025 to $3.8B in Q2 2026.
What drove Viatris's revenue change in Q2 2026?
Brands +$134M (+6%); Lipitor +$64.3M (+17%); Norvasc +$17.5M (+10%).